Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Varsha Gandhi, PhD, on Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Nov

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Varsha Gandhi, PhD, on Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia

Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies

One Surgery Could Prevent Most Ovarian Cancers

ASTRO Experts Comment on the Results of the SUPREMO Trial

SLNB Alone vs Lymphadenectomy in Cervical Cancer